552 related articles for article (PubMed ID: 31194953)
1. Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes.
Vail D; Callaway NF; Ludwig CA; Saroj N; Moshfeghi DM
Am J Ophthalmol; 2019 Nov; 207():378-384. PubMed ID: 31194953
[TBL] [Abstract][Full Text] [Related]
2. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.
Moshfeghi AA; Khurana RN; Moini H; Sherman S; Reed K; Boucher N; Rahimy E
BMC Ophthalmol; 2024 May; 24(1):229. PubMed ID: 38822279
[TBL] [Abstract][Full Text] [Related]
3. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
Naser H; Koss MJ; Singh P; Koch F
Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
[TBL] [Abstract][Full Text] [Related]
4. Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries.
Lundeen EA; Andes LJ; Rein DB; Wittenborn JS; Erdem E; Gu Q; Saaddine J; Imperatore G; Chew EY
JAMA Ophthalmol; 2022 Apr; 140(4):345-353. PubMed ID: 35238912
[TBL] [Abstract][Full Text] [Related]
5. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy.
Kang EY; Chen TH; Garg SJ; Sun CC; Kang JH; Wu WC; Hung MJ; Lai CC; Cherng WJ; Hwang YS
JAMA Ophthalmol; 2019 Apr; 137(4):363-371. PubMed ID: 30629109
[TBL] [Abstract][Full Text] [Related]
6. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database.
Kawasaki R; Konta T; Nishida K
Diabetes Obes Metab; 2018 Oct; 20(10):2351-2360. PubMed ID: 29790265
[TBL] [Abstract][Full Text] [Related]
9. Statin use and the risk of progression to vision threatening diabetic retinopathy.
Meer E; Bavinger JC; Yu Y; Hua P; McGeehan B; VanderBeek BL
Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):652-660. PubMed ID: 35253307
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity.
Zafar S; Smith K; Boland MV; Weng CY; Solomon S; Channa R
Curr Eye Res; 2020 Jul; 45(7):879-887. PubMed ID: 31829753
[TBL] [Abstract][Full Text] [Related]
11. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
12. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
13. Improved outcome after primary vitrectomy in diabetic patients treated with statins.
Tuuminen R; Sahanne S; Haukka J; Loukovaara S
Eur J Ophthalmol; 2016; 26(2):174-81. PubMed ID: 26350989
[TBL] [Abstract][Full Text] [Related]
14. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment.
Tuuminen R; Sahanne S; Loukovaara S
Acta Ophthalmol; 2014 Nov; 92(7):675-81. PubMed ID: 24506800
[TBL] [Abstract][Full Text] [Related]
15. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
Mukkamala L; Bhagat N; Zarbin MA
Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
[TBL] [Abstract][Full Text] [Related]
16. Management of diabetic macular edema in Japan: a review and expert opinion.
Terasaki H; Ogura Y; Kitano S; Sakamoto T; Murata T; Hirakata A; Ishibashi T
Jpn J Ophthalmol; 2018 Jan; 62(1):1-23. PubMed ID: 29210010
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema.
Jiang S; Barner JC; Park C; Ling YL
J Manag Care Spec Pharm; 2015 Sep; 21(9):735-41. PubMed ID: 26308221
[TBL] [Abstract][Full Text] [Related]
18. Microinvasive pars plana vitrectomy combined with internal limiting membrane peeling versus anti-VEGF intravitreal injection for treatment-naïve diabetic macular edema (VVV-DME study): study protocol for a randomized controlled trial.
Guo H; Li W; Nie Z; Zhang X; Jiao M; Bai S; Duan N; Li X; Hu B
Trials; 2023 Oct; 24(1):685. PubMed ID: 37875997
[TBL] [Abstract][Full Text] [Related]
19. Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.
Meer E; Bavinger JC; Yu Y; VanderBeek BL
JAMA Ophthalmol; 2022 May; 140(5):529-532. PubMed ID: 35389455
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor.
Serizawa S; Ohkoshi K; Minowa Y; Takahashi O
Jpn J Ophthalmol; 2015 Jul; 59(4):244-51. PubMed ID: 26008636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
